Cancer clinical trials in the region Bretagne
146 currently recruiting clinical trials
If you are a doctor and would like find matching clinical trials for you patients, create an account or log in
If you are a patient and would like to know if you may participate in a clinical trial, please consult your doctor so that he can send your file to a matching trial
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
EGFR
Targeted therapy
Systemic Treatment-Naive
Janssen
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Locally Advanced
Metastatic
EGFR
None
Systemic Treatment-Naive
Janssen
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
EGFR
None
Chemotherapy
Radiotherapy
AstraZeneca
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Localized
ALK
None
Systemic Treatment-Naive
Surgery
Hoffmann-La Roche
Early Access
Lung cancer
NSCLC (Non-Small Cell Lung Cancer)
Localized
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
None
Systemic Treatment-Naive
ALK
EGFR
Bristol-Myers Squibb
Early Access
Lung cancer
SCLC (Small Cell Lung Cancer)
Localized
Locally Advanced
None
Chemotherapy
Radiotherapy
Chemotherapy
Radiotherapy
AstraZeneca
Phase 3
Lung cancer
#NCT05920356
NSCLC (Non-Small Cell Lung Cancer)
Non-squamous NSCLC
Locally Advanced
Metastatic
KRAS G12C
PDL1 Negative (< 1%)
None
Systemic Treatment-Naive
Targeted therapy
Immunotherapy
Chemotherapy
Targeted therapy
Car-T
Bispecific T-cell engager antibodies
Antibody Drug Conjugates (ADC)
CHU de Rennes - Hôpital Pontchaillou (Rennes), Centre Hospitalier de Cornouaille (Quimper)
Amgen
Phase 3
Breast cancer
#NCT06760637
HER2 Negative
HR Positive
Locally Advanced
Metastatic
None
Systemic Treatment-Naive
Centre Eugene Marquis (Rennes)
Pfizer
Phase 3
Bladder / Urinary Tract / Urethral cancer
#NCT06319820
Non-invasive bladder cancer
Localized
FGFR
None
1
2
3 or more
CHU de Rennes - Hôpital Pontchaillou (Rennes)
Janssen
Phase 3
Lung cancer
#NCT06635824
NSCLC (Non-Small Cell Lung Cancer)
Metastatic
PDL1 Positive (1% <= X < 25%)
PDL1 Positive (25% <= X < 50%)
PDL1 Positive (>= 50%)
1
2
Immunotherapy
Chemotherapy
ALK
BRAF
EGFR
KRAS G12C
KRAS non G12C
MET
RET
ROS-1
Systemic Treatment-Naive
Car-T
CHU de Rennes - Hôpital Pontchaillou (Rennes)
Genmab